FDA clears lung AI algorithms
Icometrix recently announced that the FDA cleared the clinical use of its lung AI algorithm to quickly quantify lung pathology on chest CT scans in COVID-19 patients.
The Icolung AI algorithm is able to quantify the degree of lung involvement in coronavirus patients on CT in different lung regions in different types of CT findings, including ground-glass opacity, and crazy paving pattern. The system will enable objectivity in assessing regional lung pathology and will assist with the risk-based triage of coronavirus patients with moderate to severe symptoms, according to the company.
“AI should complement radiologists, extending beyond the detection of lung abnormalities to identifying COVID-suggestive patterns and quantifying lung involvement to support risk assessment,” VP and chief technology officer at RadNet Lawrence Tannenbaum said in a news release.
Icolung quantifies total and regional lesion burden and returns a report with annotated images directly to hospitals PACS within 10 minutes, according to the company. As the company further and improves and develops its algorithm, the updates are automatically deployed to users through the cloud.
The company received CE Mark approval for clinical use in Europe on April 23.